Fig. 2: Characterization of T-AsiG-CPL.
From: Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine
a Representative TEM images of the CPL-based nanoparticles from three independent experiments. Scale bar, 50 nm. b Size distribution of the CPL-based nanoparticles measured by dynamic light scattering. c Zeta potential of the CPL-based nanoparticles in PBS (pH 7.4) (n = 3 independent experiments). d Agarose gel electrophoresis assay of siRNA at various weight ratios of liposome to AsiG. e Quantitative analysis of the normalized siRNA intensities of AsiG-CPL and T-AsiG-CPL in the agarose gel electrophoresis assay from three independent experiments. f TEM images of CPL and T-AsiG-CPL at pH 6.5 were taken at different times in three independent experiments. Scale bar, 50 nm. g Cumulative release profiles of TPCA-1 from T-AsiG-CPL in PBS at pH 7.4 or 6.5 within 48 h (n = 3 independent experiments). h Agarose gel electrophoresis retardation assay of siG treated with 5 mM GSH for 2 h at pH 7.4 or 6.5 from three independent experiments. i siG protection assay of different nanosystems treated with RNase A for 2 h at pH 7.4 or 6.5 from three independent experiments. The data in (c, e, and g) are shown as the mean ± standard error (SEM). Source data are provided as a Source Data file.
